TY  - CONF
AU  - Munoz-Barrera, L.
AU  - Perez-Sanchez, C.
AU  - Contreras, A. Escudero
AU  - Aguirre-Zamorano, M. A.
AU  - Gutierrez, J. Calvo
AU  - Castro, R. Ortega
AU  - Romero-Gomez, M.
AU  - Sanchez-Pareja, I.
AU  - Abalos-Aguilera, M. C.
AU  - Puerto, N. Barbarroja
AU  - Venegas, J. J. Perez
AU  - Ruiz-Montesinos, D.
AU  - Rodriguez-Escalera, C.
AU  - Romero-Barco, C. M.
AU  - Mena-Vazquez, N.
AU  - Fernandez-Nebro, A.
AU  - Uceda, J.
AU  - Marenco, J. L.
AU  - Estevez, E. Collantes
AU  - Lopez-Pedreraon, C.
PY  - 2022
DO  - 10.1136/annrheumdis-2022-eular.4466
SN  - 0003-4967
UR  - http://hdl.handle.net/10668/20117
T2  - Annals of the rheumatic diseases
AB  - Background: The clinical outcome of the most common therapeutic options of rheumatoid arthritis (RA) patients, such as conventional disease-modifying antirheumatic drugs (DMARDs) and TNF inhibitors (TNFi) is still unpredictable, since a high...
LA  - en
PB  - BMJ Group
TI  - THE ANALYSIS OF THE INFLAMMATORY PROTEOME IN RHEUMATOID ARTHRITIS IDENTIFIES COMMON SIGNATURES ASSOCIATED WITH THE CLINICAL RESPONSE TO DMARDS AND TNFI THERAPIES
TY  - Conference output
VL  - 81
ER  -